Вы искали: psoriasisstudie (Датский - Английский)

psoriasisstudie 1
psoriasis study 1

lignende sygdomsalvorlighed blev set i psoriasisstudie 3.
similar disease severity was also seen in psoriasis study 3.

psoriasisstudie 1 (erasure) evaluerede 738 patienter.
psoriasis study 1 (erasure) evaluated 738 patients.

psoriasisstudie 2 (fixture) evaluerede 1.306 patienter.
psoriasis study 2 (fixture) evaluated 1,306 patients.

i psoriasisstudie 1 (phoenix 1) blev 766 patienter vurderet.
psoriasis study 1 (phoenix 1) evaluated 766 patients.

i et supplerende psoriasisstudie (clear) blev 676 patienter evalueret.
in an additional psoriasis study (clear) 676 patients were evaluated.

tabel 3 resume af klinisk virkning på psoriasisstudie 2 (fixture)
table 3 summary of clinical response on psoriasis study 2 (fixture)

tabel 5 oversigt over klinisk respons i uge 12 i psoriasisstudie 3 (accept)
table 5 summary of clinical response at week 12 in psoriasis study 3 (accept)

lignende signifikante forbedringer blev set i psoriasisstudie 2 i uge 4 og 12, som blev opretholdt til og med uge 24.
similarly, significant improvements were seen in psoriasis study 2 at week 4 and 12, which were sustained through week 24.

tabel 4 oversigt over klinisk respons i psoriasisstudie 1 (phoenix 1) og psoriasisstudie 2 (phoenix 2)
table 4 summary of clinical response in psoriasis study 1 (phoenix 1) and psoriasis study 2 (phoenix 2)

i psoriasisstudie 1 var opretholdelsen af pasi 75 signifikant bedre ved fortsat behandling sammenlignet med behandlingsophør (p < 0,001).
in psoriasis study 1 maintenance of pasi 75 was significantly superior with continuous treatment compared with treatment withdrawal (p < 0.001).

i psoriasisstudie 1 blev der påvist signifikante forbedringer i uge 2 og uge 12 af dlqi (dermatology life quality index) i forhold til baseline for hver behandlingsgruppe med ustekinumab sammenlignet med placebo.
in psoriasis study 1, at week 2 and week 12, significantly greater improvements from baseline were demonstrated in the dlqi in each ustekinumab treatment group compared with placebo.

omtrent en tredjedel (psoriasisstudie 1) og en fjerdedel (psoriasisstudie 2) af forsøgspersonerne havde psoriasisartritis (psa).
approximately one third (psoriasis study 1) and one quarter (psoriasis study 2) of subjects had psoriatic arthritis (psa).

de infektionsrater, der er blevet observeret i kliniske studier vedrørende psoriasisartrit og ankyloserende spondylitis, svarede til dem, der blev observeret i psoriasisstudierne.
infection rates observed in psoriatic arthritis and ankylosing spondylitis clinical studies were similar to those observed in the psoriasis studies.